Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Xi Wang, Jing Ni, Chen Long Hsu, Sharlin Johnykutty, Ping Tang, Yuan Soon Ho, Chia Hwa Lee, Shuyuang Yeh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.

Original languageEnglish
Pages (from-to)971-977
Number of pages7
JournalCancer Investigation
Volume27
Issue number10
DOIs
Publication statusPublished - Nov 13 2009

Keywords

  • BCa
  • TAP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer'. Together they form a unique fingerprint.

  • Cite this